As part of a series of white papers tracking clinical trials activity across the world, GlobalData recently compiled a summary of the clinical trials initiated in 2016. The company captured records of 14,190 clinical trials across all diseases and phases that had a start date between 1 January and 31 December, 2016.
GlobalData analysed the dataset to identify the top 10 drugs investigated in industry-sponsored clinical trials in 2016. The top three drugs were nivolumab, pembrolizumab, and atezolizumab, with a total of 39, 37, and 24 clinical trials, respectively. These were followed by paclitaxel, cannabidiol, adalimumab biosimilar, secukinumab, bupivacaine, ipilimumab, and adalimumab.
The majority of the trials initiated for these drugs were Phase III trials, closely followed by Phase II trials, as shown in Figure 1. Immuno-oncology drugs nivolumab and pembrolizumab topped the drugs used in industry-sponsored clinical trials in 2016. The overall dominance of monoclonal antibodies in clinical trials was clearly evident, with seven out of the top ten drugs being monoclonal antibodies.